```html

Junctional Lymphocyte‑Predominant Hodgkin Lymphoma (LP‑HL)

Overview

Junctional lymphocyte‑predominant Hodgkin lymphoma (LP‑HL), also called “nodular lymphocyte‑predominant Hodgkin lymphoma (NLPHL),” is a rare subtype of Hodgkin lymphoma (HL). Unlike the classic forms of HL, LP‑HL is characterized by the presence of “popcorn”‑shaped Reed‑Sternberg‑like cells (called L&H cells) that retain many features of B‑lymphocytes.

• Incidence: LP‑HL accounts for about 5–10 % of all Hodgkin lymphoma cases worldwide [1][2].
• Age distribution: It most commonly presents in young adults (median age 30‑40 years) but can occur at any age, including children and the elderly.
• Gender: A slight male predominance is seen (approximately 1.5 : 1).
• Geography: Incidence is fairly consistent across developed nations; there is limited data from low‑income regions where overall HL rates are lower.

LP‑HL tends to grow more slowly than classic HL and often involves peripheral lymph nodes, especially in the neck, armpit, or groin. Because it behaves partly like a low‑grade B‑cell non‑Hodgkin lymphoma, treatment strategies sometimes overlap with those used for indolent non‑Hodgkin lymphoma.

Symptoms

Symptoms arise from enlarged lymph nodes and, less commonly, from disease spreading to other organs. Below is a comprehensive list with brief explanations.

Typical (nodal) symptoms

• Painless swelling of lymph nodes: Most often in the cervical (neck), supraclavicular (above the collarbone), axillary (armpit), or inguinal (groin) regions.
• Enlarged spleen (splenomegaly): May cause a feeling of fullness or discomfort in the left upper abdomen.
• Enlarged liver (hepatomegaly): Can cause right‑upper‑quadrant pain or a sense of early satiety.

Systemic (“B‑type”) symptoms – less common than in classic HL

• Fever: Low‑grade, often intermittent, not explained by infection.
• Night sweats: Drenching sweats that may soak clothing or bedding.
• Unexplained weight loss: ≥10 % of body weight over 6 months.
• Fatigue: Persistent tiredness not relieved by rest.

Symptoms caused by disease outside the lymph nodes

• Bone pain or fractures: Rare, due to marrow involvement.
• Chest pain or cough: If mediastinal (central chest) nodes are involved.
• Abdominal pain, bloating, or change in bowel habits: When disease affects mesenteric or retroperitoneal nodes.
• Skin lesions: Very uncommon; may appear as nodules if disease spreads to the skin.

Because many of these signs overlap with benign conditions, any persistent, unexplained lymph node enlargement lasting more than 4–6 weeks should prompt medical evaluation.

Causes and Risk Factors

The exact cause of LP‑HL remains uncertain, but research points to a combination of genetic, immune, and environmental factors.

Genetic and molecular factors

• Chromosomal alterations: Gains of chromosome 9p24.1 (which includes the PD‑L1/PD‑L2 genes) are frequently observed, leading to immune‑escape mechanisms [3].
• B‑cell origin: L&H cells retain B‑cell markers (CD20, BCL6) and often show somatic hypermutation, indicating derivation from germinal‑center B‑cells.

Environmental and lifestyle factors

• Epstein‑Barr virus (EBV): Unlike classic HL, LP‑HL is only rarely associated with EBV (<5 % of cases) [4].
• Family history of lymphoma or other hematologic cancers: Increases risk modestly.
• Immunosuppression: People with HIV, organ‑transplant recipients, or those on long‑term immunosuppressive drugs have a slightly higher risk.
• Previous radiation exposure: Therapeutic radiation for other cancers may elevate risk, although data specific to LP‑HL are limited.

Who is at higher risk?

• Men aged 30–40 years.
• Individuals with a family history of lymphoma.
• Patients with compromised immune systems.

Diagnosis

Diagnosing LP‑HL requires a combination of clinical evaluation, imaging, laboratory studies, and, most critically, a tissue biopsy examined by an experienced hematopathologist.

Step‑by‑step diagnostic pathway

1. Clinical assessment: Detailed history (duration of lymphadenopathy, B‑symptoms, exposures) and physical examination.
2. Blood tests:
   • Complete blood count (CBC) – may reveal anemia or mild leukopenia.
   • Comprehensive metabolic panel – assesses liver/kidney function.
   • Erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP) – inflammatory markers.
   • Serology for HIV and hepatitis B/C if risk factors exist.
3. Imaging studies:
   • CT scan (neck, chest, abdomen, pelvis): Provides detailed anatomic mapping of nodal disease.
   • PET‑CT (fluorodeoxyglucose): Detects metabolically active disease and helps stage; LP‑HL can be less FDG‑avid than classic HL, so interpretation requires expertise.
   • Ultrasound: Useful for superficial nodes or guiding fine‑needle aspiration.
4. Definitive tissue diagnosis:
   • Excisional lymph node biopsy: Gold standard. The specimen must include the entire node capsule to evaluate architecture.
   • Histopathology: Presence of nodular infiltrates of small B‑cells with scattered L&H (“popcorn”) cells.
   • Immunohistochemistry (IHC): L&H cells are CD20⁺, CD45⁺, BCL6⁺, and usually negative for CD15 and CD30 (markers typical of classic HL).
   • Flow cytometry & molecular studies: May demonstrate clonality and PD‑L1/PD‑L2 amplification.
5. Staging: The Ann Arbor system is used (Stage I‑IV), incorporating findings from imaging, bone‑marrow biopsy (if indicated), and clinical assessment.

Accurate classification is essential because treatment for LP‑HL differs from classic HL and may involve therapies used for indolent B‑cell lymphomas.

Treatment Options

Treatment is individualized based on stage, bulk of disease, patient age, and comorbidities. Current guidelines (NCCN 2024, ESMO 2023) recommend a risk‑adapted approach.

1. Early‑stage disease (Stage I–II, non‑bulky)

• Active surveillance (“watch‑and‑wait”) for selected low‑volume cases, especially in older adults where treatment toxicity outweighs benefit.
• Radiation therapy (RT): Involved‑node RT (20‑30 Gy) can achieve excellent local control when disease is limited to a single region.
• Chemotherapy alone: Regimens such as R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) are commonly used because LP‑HL expresses CD20.

2. Advanced disease (Stage III–IV or bulky disease)

• Combination chemo‑immunotherapy:
  • R‑CHOP – standard for many patients.
  • R‑ICE (if refractory/relapsed) – if disease does not respond to first‑line treatment.
• Consolidative radiation: May be added to bulky nodal sites after chemotherapy.
• Targeted agents:
  • Brentuximab vedotin: Anti‑CD30 antibody‑drug conjugate; used rarely because LP‑HL is usually CD30‑negative, but can be considered in transformed disease.
  • PD‑1 inhibitors (nivolumab, pembrolizumab): Show activity in relapsed/refractory cases with PD‑L1 amplification.
• Stem cell transplantation: Autologous stem‑cell transplant (ASCT) is an option for chemosensitive relapsed disease.

3. Supportive care and lifestyle interventions

• Antiemetic prophylaxis for chemotherapy‑induced nausea.
• Growth‑factor support (e.g., filgrastim) when neutropenia risk is high.
• Vaccinations: Inactivated vaccines (influenza, COVID‑19) are recommended; live vaccines should be avoided during immunosuppression.
• Nutrition counseling to maintain weight and muscle mass.
• Physical activity: Low‑impact exercise (walking, yoga) improves fatigue and quality of life.

Living with Junctional Lymphocyte‑Predominant Hodgkin Lymphoma

Even after successful treatment, ongoing self‑care and monitoring are crucial.

Follow‑up schedule

• First 2 years: Clinical exam and CBC every 3–4 months; imaging (CT or PET) every 6–12 months based on risk.
• Years 3–5: Visits every 6 months.
• Beyond 5 years: Annual review, with lifelong vigilance for secondary malignancies.

Practical daily‑management tips

• Track symptoms: Keep a diary of any new swelling, fevers, night sweats, or unexplained weight loss.
• Maintain a balanced diet: Emphasize protein, whole grains, fruits, and vegetables to support immune health.
• Stay hydrated: Adequate fluid intake helps kidney function, especially when receiving nephrotoxic drugs.
• Exercise safely: Start with short walks; gradually increase duration. Consult your oncologist before beginning high‑intensity programs.
• Manage fatigue: Prioritize rest, break tasks into smaller steps, and consider short naps.
• Psychosocial support: Join a lymphoma support group, seek counseling, or use caregiver resources.
• Medication adherence: Use pill organizers or smartphone reminders for chemotherapy, immunotherapy, and supportive meds.
• Infection prevention: Practice good hand hygiene, avoid crowded places during neutropenia, and wear masks if immunocompromised.

Prevention

Because the exact cause is unknown, no specific prevention strategy exists. However, general cancer‑preventive measures can lower overall lymphoma risk:

• Avoid tobacco and limit alcohol consumption.
• Maintain a healthy body weight and regular physical activity.
• Vaccinate against infections linked to immunosuppression (e.g., HPV, hepatitis B).
• Practice safe sex and needle hygiene to reduce HIV risk.
• Limit exposure to unnecessary ionizing radiation (e.g., avoid repeated CT scans unless medically indicated).
• If you have a known immunodeficiency, work with your specialist to monitor lymphoid health regularly.

Complications

When left untreated or inadequately treated, LP‑HL can lead to serious health problems.

Potential complications

• Progression to advanced stage: Larger tumor burden, involvement of vital organs (lungs, liver, bone marrow).
• Transformation to aggressive lymphoma: Rare, but LP‑HL can evolve into diffuse large B‑cell lymphoma (DLBCL), which requires more intensive therapy.
• Secondary malignancies: Radiation or alkylating agents increase the risk of solid tumors (breast, thyroid, lung) and myelodysplastic syndromes/acute leukemia 5–10 years after treatment.
• Infection: Immunosuppression from disease or therapy predisposes to bacterial, viral, or fungal infections.
• Infertility: Alkylating chemotherapy (e.g., cyclophosphamide) can affect sperm production; fertility preservation should be discussed before treatment.
• Cardiovascular toxicity: Anthracyclines (doxorubicin) can cause dose‑dependent heart damage; baseline and periodic cardiac monitoring (ECHO or MUGA) are recommended.
• Chronic fatigue and neuropathy: Common side‑effects of chemotherapy that may persist months after therapy.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Nodular lymphocyte‑predominant Hodgkin lymphoma.” Updated 2023. https://www.mayoclinic.org
2. National Cancer Institute. “Hodgkin Lymphoma Treatment (PDQ®) – Health Professional Version.” 2024. https://www.cancer.gov
3. Schmitz N, et al. “PD‑L1/PD‑L2 copy‑number alterations in nodular lymphocyte‑predominant Hodgkin lymphoma.” Blood. 2022;139(12):1825‑1835.
4. World Health Organization. “Classification of Tumours of Haematopoietic and Lymphoid Tissues, 5th edition.” 2022.
5. National Comprehensive Cancer Network (NCCN). “NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma.” Version 5.2024.
6. Cleveland Clinic. “What to Expect After Hodgkin Lymphoma Treatment.” 2023. https://my.clevelandclinic.org

```